Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica's EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwideAware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing changes in their breastsFirst order placed for both Colon Disease ...

- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. - Company receives notice of allowance for five new patents in Europe, Canada and Japan; the inFoods technology now has 25 Issued/allowed p ...

Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024  InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syndrome (IBS) Clinical Session  Company in discussions with Key Clinical Lab Customers for Use of its Recently US FDA 510(k) Cleared Hp Detect™ Test Product, Designed to Detect the Presence of the H. pylori Bacteria that i ...

On July 20, 2020, the Company filed with the Securities and Exchange Commission ("SEC") a Form S-3 shelf registration statement and base prospectus which was declared effective by the SEC on September 30, 2020. This shelf registration statement registered the sale of up to $90,000,000 of the Company's equity securities during the three years ended September 30, 2023. For the three months ended February 29, 2024, the Company had three key customers who are located in the United States and Aisa which accounte ...

Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Me ...

Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share reflecting disciplined operating expense management.Company Received US FDA 510(k) Clearance for Its Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects approximately 35% of the U.S. Population. IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOMERICA, INC. (Exact name of registrant as specified in its charter) Delaware 95-2645573 (State or other jurisdiction of incorporation of organization) (I.R.S. Employer Identification No.) 17571 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbols Name of each exchange on which registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of ...

We use hazardous materials in our research and production. The risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any harm or damages that result and any such liability could exceed the resources of the Company. The Company may incur substantial costs to comply with environmental regulations. Companies in or related to our industry often aggressively protect and pursue their intellectual prop ...

Table of Contents | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------|-------|------------------------|-------|-------------------------|-------|----------------|----------------| | | | Nine Months \n2023 | Ended | February 28, \n2022 | | Increase \n$ | (Decrease) \n% | | Clinical lab | $ | 2,580,000 | $ | 2,259,000 | $ | 321,000 | 14% | | Over-the-counter | | 971,000 | | 857,000 | | 114,000 | 13% | | Contract manufacturing | | 431,000 | | 319,000 | | 112,000 | 35% | | Physician's ...